Close Menu

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Transgenomic this week reported first-quarter revenue growth of 8 percent, with instrument sales up 12 percent year over year.

The Omaha, Neb.-based firm took in total revenues of $5.4 million for the three-month period ended March 31, compared to $5 million for the first quarter of 2009.

Transgenomic cut its net loss by nearly two-thirds to $324,000, or $.01 per share, from $953,000, or $.02 per share, for the first quarter of 2009.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal reports on the struggle to meet the demand for rapid COVID-19 testing.

The Newsroom reports New Zealand is using genomics to trace the origins of its new coronavirus outbreak.

In Nature this week: researchers in Canada sequence the genome of the black mustard plant Brassica nigra, and more.

According to Bloomberg, Moderna has a $1.5 billion vaccine deal with the US to provide 100 million doses.

Aug
18
Sponsored by
Bio-Rad

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug
19
Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Aug
24
Sponsored by
IONPath

This webinar will discuss how high-definition spatial proteomics, enabled by Multiplexed Ion Beam Imaging (MIBI), can be used to explore the immune microenvironment of tumor biopsy samples, illustrated by a case study at Dana-Farber Cancer Institute.

Aug
25
Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.